Safety Data on the Novel Pancreatic Cancer Drug Available by Early Access

(MedPage Today) -- The investigational drug daraxonrasib, now available through an early access program, demonstrated promising efficacy in previously treated pancreatic ductal adenocarcinoma (PDAC) and was associated with high-grade adverse events...
Source
MedPage Today
Opens original article in a new tab



